Healthy Volunteer Study: Clinical Trials

45 trials for Healthy Volunteer Study, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

42 completed, 2 recruiting, 1 not yet recruiting. 45 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 145Completed 42, Recruiting 2, Not yet recruiting 1

Follow Healthy Volunteer Study: new trials by email Literature Review of Healthy Volunteer Study trials Research Report on Healthy Volunteer Study

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety Study of CZ10 in Healthy Volunteers
Contrast Media, Placebo - Healthy Volunteer Study
Phase 1Not yet recruitingNextrast, Inc.242050-01-012024-11-29
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
PF-08103402, Placebo, Midazolam - Healthy Volunteer Study, Healthy Adults
Phase 1RecruitingPfizer1332026-06-172026-11-03
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.242025-12-042026-04-13
Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.202025-05-092025-08-29
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
Xenon gas inhalation - Healthy Volunteer Study
Phase 1RecruitingGeneral Biophysics LLC162025-04-162025-04-25
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination - Healthy Volunteer Study, Hepatic Impairment
Phase 1CompletedAtea Pharmaceuticals, Inc.282025-04-092026-07-31
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.382025-04-082025-08-29
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
ALG-055009 - Healthy Volunteer Study
Phase 1CompletedAligos Therapeutics82025-03-252025-07-09
A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects
CG001419, Placebo - Healthy Volunteer Study, Pain Management
Phase 1CompletedCullgen Australia Pty Ltd722025-01-222026-02-20
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.302025-01-072026-10-28
Phase 1 BIO 300 Oral Suspension
BIO 300 Oral Suspension - Healthy Volunteer Study
Phase 1CompletedHumanetics Corporation562024-12-232025-10-30
A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers
TRX-100, Placebo - Healthy Volunteer Study
Phase 1CompletedTraws Pharma, Inc.662024-08-132026-01-21
Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.282024-04-152024-07-31
A Clinical Study of AK0610
AK0610 Injection solution, Placebo - Healthy Volunteer Study
Phase 1CompletedShanghai Ark Biopharmaceutical Co., Ltd.1472024-02-292026-10-28
Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
Fixed-Dose Combination (FDC) Tablet - Healthy Volunteer Study
Phase 1CompletedNewAmsterdam Pharma282024-01-202024-06-05
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.422023-12-142024-09-19
Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers
Azelaprag - Healthy Volunteer Study
Phase 1CompletedBioAge Labs, Inc.162023-11-172024-02-23
Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.
BEN8744, Matching Placebo - Healthy Volunteer Study
Phase 1CompletedBenevolentAI Bio762023-08-302025-05-07
The Study of Bemnifosbuvir in Healthy Japanese Subjects
Bemnifosbuvir (BEM) - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.142023-04-262023-06-15
Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
Bemnifosbuvir (BEM), Placebo, Moxifloxacin - Healthy Volunteer Study
Phase 1CompletedAtea Pharmaceuticals, Inc.352023-04-252023-06-15

Showing 20 of 45. Sign in to see all of them.

Narrower conditions

Acute Pain (1)  ·  Acute Radiation Syndrome (1)  ·  Agnosia (1)  ·  Asthma (1)  ·  Chronic Pain (1)  ·  Opioid-Related Disorders (1)  ·  Renal Insufficiency (1)  ·  Respiratory Aspiration (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (3)  ·  Neurologic Manifestations (2)  ·  Respiratory Tract Diseases (2)  ·  Signs and Symptoms (2)  ·  Bronchial Diseases (1)  ·  Chemically-Induced Disorders (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Hypersensitivity (1)  ·  Hypersensitivity, Immediate (1)  ·  Immune System Diseases (1)  ·  Kidney Diseases (1)  ·  Lung Diseases (1)  ·  Lung Diseases, Obstructive (1)  ·  Male Urogenital Diseases (1)

Interventions

AT-511 (12)  ·  ruzasvir (3)  ·  Ibuprofen (2)  ·  Midazolam (2)  ·  Tablets (2)  ·  Acetaminophen (1)  ·  Buprenorphine (1)  ·  Carbamazepine (1)  ·  Contrast Media (1)  ·  Cyclosporine (1)  ·  Fluticasone-Salmeterol Drug Combination (1)  ·  LY 2140023 (1)  ·  Lead (1)  ·  Levonorgestrel (1)  ·  Moxifloxacin (1)

Sponsors

Atea Pharmaceuticals, Inc. (18)  ·  Orion Corporation, Orion Pharma (3)  ·  Pfizer (2)  ·  Reckitt Benckiser Healthcare (UK) Limited (2)  ·  Aligos Therapeutics (1)  ·  AstraZeneca (1)  ·  BenevolentAI Bio (1)  ·  BioAge Labs, Inc. (1)  ·  Cullgen Australia Pty Ltd (1)  ·  Dauntless Pharmaceuticals (1)  ·  Denovo Biopharma LLC (1)  ·  Exicure, Inc. (1)  ·  General Biophysics LLC (1)  ·  Humanetics Corporation (1)  ·  Kinoxis Therapeutics Pty Ltd (1)

Countries

United States (15)  ·  Canada (12)  ·  United Kingdom (8)  ·  Australia (3)  ·  Finland (2)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  New Zealand (1)

Top investigators

Denisa Wilkes (1)  ·  Girish Sharma, MBBS (1)  ·  Haleema Shakur-Still (1)  ·  Howard L Weiner, MD (1)  ·  Ian Roberts (1)  ·  Ilya Ilin, PhD (1)  ·  James C Eisenach, MD (1)  ·  Jeffrey Zacher, MD (1)  ·  Jo Collier, Dr,MB, ChB (1)  ·  John Whiteside (1)  ·  Maria Annunen, MSc (1)  ·  Mika Scheinin, MD, PhD (1)  ·  Patrick Martin, MD (1)

Results publications

PMID 29667449, PMID 30977980, PMID 34998508, PMID 36582243, PMID 40121179

NIH funding

1UG3DA048743-01 (1), 2014 (1), P01NS119159 (1), R42AG073059 (1)